CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total Shareholders' Equity Attributable to Bruker Corporation	Noncontrolling Interests in Consolidated Subsidiaries
Balance at beginning of period at Dec. 31, 2020	$ 974.3		$ 1.7	$ (667.0)	$ 216.3	$ 1,406.5	$ 3.7	$ 961.2	$ 13.1
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	11.7				11.7			11.7
Stock options exercised (in shares)			580,656
Restricted stock units vested	(4.7)				(4.7)			(4.7)
Restricted stock units vested (in shares)			278,769
Stock based compensation	14.5				14.5			14.5
Shares repurchased	(153.3)			$ (153.3)				(153.3)
Shares repurchased (in shares)			(2,092,819)	2,092,819
Cash dividends paid to common shareholders	(24.1)					(24.1)		(24.1)
Formation of Acuity Spatial Genomics Inc.		$ 0.3
Consolidated net (loss) income	280.7	(0.1)				277.1		277.1	3.6
Other comprehensive income (loss) income	(14.5)						(11.9)	(11.9)	(2.6)
Balance at end of period at Dec. 31, 2021	1,084.6	0.2	$ 1.7	$ (820.3)	237.8	1,659.5	(8.2)	1,070.5	14.1
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	5.8				5.8			5.8
Stock options exercised (in shares)			251,006
Restricted stock units vested	(3.0)				(3.0)			(3.0)
Restricted stock units vested (in shares)			233,545
Stock based compensation	15.7				15.7			15.7
Shares repurchased	(264.7)			$ (264.7)				(264.7)
Shares repurchased (in shares)			(4,215,094)	4,215,094
Cash dividends paid to common shareholders	(29.8)					(29.8)		(29.8)
Distributions to noncontrolling interests	(1.2)								(1.2)
Consolidated net (loss) income	299.1	(0.6)				296.6		296.6	2.5
PreOmics Acquisition - other shareholders		6.8
Acquisition of minority interest	(3.1)					(0.3)	(0.2)	(0.5)	(2.6)
Other comprehensive income (loss) income	22.3	(0.3)					23.2	23.2	(0.9)
Balance at end of period at Dec. 31, 2022	1,125.7	6.1	$ 1.7	$ (1,085.0)	256.3	1,926.0	14.8	1,113.8	11.9
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442
Increase (Decrease) in Stockholders' Equity
Stock options exercised	9.7				9.7			9.7
Stock options exercised (in shares)			285,030
Restricted stock units vested	(3.4)				(3.4)			(3.4)
Restricted stock units vested (in shares)			215,959
Stock based compensation	17.6	0.1			17.6			17.6
Shares repurchased	(153.4)			$ (152.2)	(1.2)			(153.4)
Shares repurchased (in shares)			(2,412,437)	2,412,437
Employee stock purchase plan	3.9				3.9			3.9
Employee stock purchase plan (in shares)			53,130
Cash dividends paid to common shareholders	(29.4)					(29.4)		(29.4)
Cash dividends paid to common shareholders	5.0								5.0
Other shareholders of majority-owned acquisitions		12.6
Distributions to noncontrolling interests	(2.0)								(2.0)
Consolidated net (loss) income	429.2	(0.7)				427.2		427.2	2.0
Other comprehensive income (loss) income	(8.3)	0.6					(8.8)	(8.8)	0.5
Balance at end of period at Dec. 31, 2023	$ 1,394.6	$ 18.7	$ 1.7	$ (1,237.2)	$ 282.9	$ 2,323.8	$ 6.0	$ 1,377.2	$ 17.4
Balance (in shares) at Dec. 31, 2023			145,164,826	30,778,879